9.23.09 Pediatrics Grand Rounds Evaluation
Exit this survey 

1. A New Drug for Infant Leukemia and the Cell Death Mechanism that it Activates

 
Carolyn A. Felix, MD
Professor of Pediatrics, University of Pennsylvania School of Medicine
Attending Physician, Division of Oncology
Children's Hospital of Philadelphia
September 23, 2009

Teaching Objectives:
The participant will be able to:
1. Understand deregulated pro-survival BCL-2 family cell death regulatory factors as potential molecular therapeutic targets in infant leukemias with MLL translocations
2. Define overlap between apoptosis and autophagy cell death pathways
3. Understand application of iterative phamacostatistical modeling and simulation approaches to the development of obatoclax for leukemia in infants

1. How well did this lecture fulfill the stated objectives?

2. How current was the information presented?

3. Please rate the clinical applicability of the information presented.

4. Please rate the speaker's quality of presentation.

5. Was the presentation free of commercial bias?

6. Please use this space for general comments related to this presentation.

7. We welcome your suggestions for future topics.

Thank you for taking the time to complete this evaluation. Click the DONE button below to record your responses.